Darolutamide (Nubeqa®) 300 mg tablets: clinical trials recruiting now
Fewer than 3 recruiting trials found.
2
Recruiting trials
4
Conditions studied
15
US states with sites
5
Countries
Phase breakdown
Phase 1 1
Not applicable 1
Conditions being studied
| Condition | Trials |
|---|---|
| Prostate Cancer | 2 |
| Castrate Sensitive Prostate Cancer | 1 |
| Metastatic Cancer | 1 |
| Metastatic Prostate Cancer | 1 |
Recruiting trials involving Darolutamide (Nubeqa®) 300 mg tablets
- PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
- Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Common questions
How many recruiting trials involve Darolutamide (Nubeqa®) 300 mg tablets?
2 recruiting trials across 4 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.